Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)

v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2018 $ 133,908 $ 17,528,947 $ (33,225,107) $ (15,562,252)
Balance (in shares) at Dec. 31, 2018 133,907,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense   171,493   171,493
Warrants issued in connection with convertible multi-draw credit agreement, related party   716,110   716,110
Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party   1,584,850   1,584,850
Net loss     (14,774,392) (14,774,392)
Balance at Mar. 31, 2019 $ 133,908 20,001,400 (47,999,499) (27,864,191)
Balance (in shares) at Mar. 31, 2019 133,907,747      
Balance at Dec. 31, 2018 $ 133,908 17,528,947 (33,225,107) (15,562,252)
Balance (in shares) at Dec. 31, 2018 133,907,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss       1,130,898
Balance at Jun. 30, 2019 $ 134,095 20,318,672 (32,094,209) (11,641,442)
Balance (in shares) at Jun. 30, 2019 134,095,247      
Balance at Mar. 31, 2019 $ 133,908 20,001,400 (47,999,499) (27,864,191)
Balance (in shares) at Mar. 31, 2019 133,907,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense   173,084   173,084
Series B warrant exercises $ 187 144,188   144,375
Series B warrant exercises (in shares) 187,500      
Net loss     15,905,290 15,905,290
Balance at Jun. 30, 2019 $ 134,095 20,318,672 (32,094,209) (11,641,442)
Balance (in shares) at Jun. 30, 2019 134,095,247      
Balance at Dec. 31, 2019 $ 182,895 32,538,445 (32,173,282) 548,058
Balance (in shares) at Dec. 31, 2019 182,895,247      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense   64,142   64,142
Series B warrant exercises $ 313 26,250   26,563
Series B warrant exercises (in shares) 312,500      
Net loss     (2,341,660) (2,341,660)
Balance at Mar. 31, 2020 $ 183,208 32,628,837 (34,514,942) (1,702,897)
Balance (in shares) at Mar. 31, 2020 183,207,747      
Balance at Dec. 31, 2019 $ 182,895 32,538,445 (32,173,282) 548,058
Balance (in shares) at Dec. 31, 2019 182,895,247      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net loss       (3,761,896)
Balance at Jun. 30, 2020 $ 183,208 32,657,546 (35,935,178) (3,094,424)
Balance (in shares) at Jun. 30, 2020 183,207,747      
Balance at Mar. 31, 2020 $ 183,208 32,628,837 (34,514,942) (1,702,897)
Balance (in shares) at Mar. 31, 2020 183,207,747      
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense   28,709   28,709
Net loss     (1,420,236) (1,420,236)
Balance at Jun. 30, 2020 $ 183,208 $ 32,657,546 $ (35,935,178) $ (3,094,424)
Balance (in shares) at Jun. 30, 2020 183,207,747